Research programme: antibodies - AnaptysBio/VLST
Alternative Names: ANA506Latest Information Update: 25 Jun 2014
At a glance
- Originator VLST Corporation
- Developer AnaptysBio; VLST Corporation
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation
Most Recent Events
- 25 Jun 2014 Discontinued for Autoimmune disorders in USA (unspecified route)
- 25 Jun 2014 Discontinued for Inflammation in USA (unspecified route)
- 06 Apr 2010 Early research in Autoimmune disorders and Inflammation in USA (unspecified route)